Corporate Banner
Satellite Banner
Technology Networks Header
Monday, September 01, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Phenomenex Lux™ 10-Micron Chiral Media Now Available in Bulk for Preparative Chromatography
Thursday, September 06, 2012
Phenomenex Inc. announces the extension of its successful Lux chiral media line to meet the needs of preparative chromatography applications.

Connect with Takara Bio Europe at ELRIG Drug Discovery 2012
Tuesday, September 04, 2012
Connect with Takara Bio at booth M3 at the DD2012 in Manchester and win a Google Nexus 7 tablet.

Molecular Devices to Attend ELRIG Drug Discovery 2012
Wednesday, August 15, 2012
Company to showcase their SpectraMax® Paradigm® during ELRIG, booth Q8, Manchester Central Convention Complex in Manchester, United Kingdom, 5-6 September 2012.

BASF subsidiary Metanomics Health launches MetaMap®Tox
Monday, August 13, 2012
MetaMap®Tox is a service evaluating specific metabolomic patterns in vivo, enabling customers to better and faster identify potential safety risks of test compounds in in vivo studies of rats. Developed in-house by BASF’s Experimental Toxicology and Ecology unit and marketed through Metanomics Health, MetaMap®Tox addresses key unmet needs for in vivo toxicology testing: predictability, understanding of a toxicology mechanism and the ability for translation to clinical use.

Zetasizer Nano Delivers Essential Data in Environmental Nanosafety Work in Canada
Tuesday, August 07, 2012
Researchers at the University of Alberta, Canada are working as part of a major Canadian initiative to investigate the aquatic and environmental aspects of nanoparticles.

xCELLigence System Evaluated in EU Project to Replace Animal Experiments in Cosmetics Industry
Monday, April 02, 2012
Roche’s xCELLigence RTCA System is being used in the European Union’s SEURAT initiative to run five years from 2011 to 2016.

Thermo Fisher Scientific Introduces New Screening Tool for Developmental Neurotoxicity
Monday, March 19, 2012
Offers consumer and health products Industries a high-throughput, animal-free approach to identify developmental neurotoxins.

CellMade Targets Inflammatory Biology Products and Services
Monday, March 19, 2012
Company introduces their new site, featuring free poster and protocol downloads as well as updated information on the CellInsight™ platform and REACT-lipid™ service.

Molecular Devices Introduces ScreenWorks® Peak Pro™ Software
Wednesday, February 29, 2012
Analysis model offers the ability to analyze multi-peak calcium oscillation responses of cells, and in particular beating cardiomyocytes, to characterize cardiotoxic and cardioactive compounds during a high throughput screen.

<< 1 2 3 4 5 6 7 >>
Showing Results 51 - 60 of 62
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv